Ocular TherapeutixOCUL
OCUL
About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Employees: 274
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
89% more call options, than puts
Call options by funds: $5.19M | Put options by funds: $2.74M
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
68% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 37
10% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 11 (+1) [Q4]
7% more funds holding
Funds holding: 168 [Q3] → 179 (+11) [Q4]
4.68% less ownership
Funds ownership: 89.82% [Q3] → 85.13% (-4.68%) [Q4]
6% less capital invested
Capital invested by funds: $1.22B [Q3] → $1.14B (-$77.5M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
90%
upside
Avg. target
$16.33
107%
upside
High target
$19
141%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger 45% 1-year accuracy 55 / 123 met price target | 90%upside $15 | Buy Initiated | 11 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 32% 1-year accuracy 24 / 75 met price target | 141%upside $19 | Market Outperform Maintained | 4 Mar 2025 |
HC Wainwright & Co. Yi Chen 36% 1-year accuracy 58 / 162 met price target | 90%upside $15 | Buy Reiterated | 4 Mar 2025 |
Financial journalist opinion
Based on 5 articles about OCUL published over the past 30 days
Positive
Benzinga
2 days ago
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Needham initiated coverage on Ocular Therapeutix Inc OCUL, noting the company's lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration (wet AMD).
Positive
Seeking Alpha
1 week ago
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
Neutral
Seeking Alpha
1 week ago
Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript
Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 week ago
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025.
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular's second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024
Positive
Seeking Alpha
2 months ago
Ocular Is Now Thoroughly Derisked
Ocular Therapeutics' OTX-TKI implant offers a cost-effective, long-lasting alternative to gene therapies for wet AMD, showing superior duration and comparable efficacy to Regeneron's Eylea. Recent FDA approval for trial modifications and positive phase 1 results in NPDR patients enhance OTX-TKI's potential, with phase 3 data expected by Q4 2025. Financially, OCUL is strong with a $1.34bn market cap and $427mn cash, ensuring a runway of 8-9 quarters despite high R&D expenses.
Neutral
GlobeNewsWire
2 months ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™